Thyroid Cancer Diagnostics

Global Thyroid Cancer Diagnostics Market to Reach US$6.7 Billion by 2030

The global market for Thyroid Cancer Diagnostics estimated at US$5.3 Billion in the year 2024, is expected to reach US$6.7 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Consumables & Accessories segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 6.8% CAGR

The Thyroid Cancer Diagnostics market in the U.S. is estimated at US$1.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.1% CAGR.

Global "Thyroid Cancer Diagnostics" Market – Key Trends & Drivers Summarized

How Is Thyroid Cancer Diagnostics Evolving in the Age of Precision Oncology?
The landscape of thyroid cancer diagnostics is undergoing a significant transformation, driven by advancements in molecular biology, imaging technologies, and personalized medicine. Historically reliant on palpation, ultrasound, and fine-needle aspiration (FNA), thyroid cancer detection is now increasingly supported by genomic profiling, biomarker analysis, and high-resolution imaging. These tools are enhancing diagnostic accuracy, reducing unnecessary surgeries, and enabling earlier detection of malignancies such as papillary and follicular thyroid carcinomas. The use of next-generation sequencing (NGS) panels for identifying mutations in genes like BRAF, RAS, RET, and TERT is revolutionizing how clinicians distinguish between benign and malignant nodules, particularly in cases with indeterminate cytology. Radiomics and AI-based interpretation of ultrasound data are also improving the predictive value of traditional imaging, allowing for more confident clinical decision-making. Liquid biopsies, though still emerging, hold potential for non-invasive, repeatable monitoring of disease progression and recurrence. These technological innovations are not only enhancing diagnostic precision but also supporting the broader trend toward targeted therapies and individualized treatment planning.

Are Rising Thyroid Cancer Rates Changing the Global Diagnostic Priorities?
The global incidence of thyroid cancer has been steadily increasing, particularly in regions with advanced healthcare systems, due in part to widespread use of imaging and increased awareness. This epidemiological trend is prompting public health systems and clinical practices to prioritize the early detection and differentiation of thyroid nodules, many of which are asymptomatic and discovered incidentally during unrelated imaging exams. While much of the increase is attributed to the detection of small, indolent tumors, concerns over overdiagnosis and overtreatment are fueling a shift toward more nuanced diagnostic frameworks. Emerging guidelines advocate for risk-stratified diagnostic approaches that combine imaging features, cytology, and molecular testing to tailor patient management. In Asia, particularly South Korea and China, rising case numbers have led to national screening efforts and increased investment in diagnostic infrastructure. Meanwhile, underserved regions in Africa and parts of Latin America are seeing a delayed but growing demand for diagnostic tools as awareness and access to healthcare improve. These global shifts are reshaping diagnostic workflows and intensifying demand for cost-effective, scalable, and minimally invasive technologies.

What Diagnostic Technologies Are Setting New Standards in Thyroid Cancer Detection?
The diagnostic arsenal for thyroid cancer is expanding rapidly, with innovations that span imaging, cytopathology, and molecular diagnostics. High-frequency ultrasonography remains the cornerstone of initial evaluation, but its diagnostic accuracy is now being significantly enhanced by elastography, Doppler flow analysis, and machine learning algorithms that analyze nodule morphology and vascularity. Fine-needle aspiration biopsy, the gold standard for cytological evaluation, is being supplemented with molecular testing platforms that evaluate panels of gene mutations and expression profiles. Commercial assays such as ThyroSeq, Afirma, and RosettaGX offer valuable insights into the malignancy risk of indeterminate nodules, guiding whether surgery is warranted. SPECT/CT and PET/CT imaging are playing a growing role in staging, recurrence monitoring, and therapy response assessment, particularly in high-risk or metastatic cases. AI-assisted pathology platforms are improving the consistency of cytology interpretation, reducing inter-observer variability. At the frontier, research into circulating tumor DNA (ctDNA) and microRNA signatures in blood promises to add a new layer of non-invasive surveillance. Together, these innovations are moving thyroid cancer diagnostics toward a future defined by accuracy, efficiency, and personalization.

The Growth in the Thyroid Cancer Diagnostics Market Is Driven by Several Factors…
The robust growth in the thyroid cancer diagnostics market is being fueled by a blend of technological, demographic, and healthcare policy-related factors. Rising global incidence of thyroid nodules—many requiring differentiation through advanced diagnostic techniques—is a key clinical driver. Increased use of high-resolution imaging technologies, such as ultrasound and CT scans, is uncovering a larger number of incidental thyroid nodules, many of which are being referred for diagnostic workup. The expanding availability of molecular diagnostics and genomic profiling in routine clinical practice is enabling more precise evaluation of indeterminate cases, thereby reducing diagnostic uncertainty and improving patient management pathways. Moreover, shifting clinical guidelines toward risk-based, personalized approaches to thyroid nodule evaluation are pushing hospitals and diagnostic labs to invest in integrated diagnostic platforms. Patient demand for non-invasive and accurate diagnostics is also influencing the adoption of liquid biopsy and advanced imaging tools. Aging populations, rising healthcare access in emerging economies, and growing awareness about endocrine cancers are further boosting diagnostic volumes. Additionally, the trend toward value-based care and outcome optimization is encouraging providers to adopt technologies that reduce unnecessary procedures and improve diagnostic accuracy, reinforcing the market momentum for advanced thyroid cancer diagnostics.

SCOPE OF STUDY:

The report analyzes the Thyroid Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Instruments, Consumables & Accessories); Test Type (Imaging Test, Biopsy, Blood Test, Other Test Types); End-Use (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• Agilent Technologies Inc.
• Bayer AG
• Bio-Rad Laboratories Inc.
• bioMérieux SA
• Canon Inc.
• Cepheid
• DiaSorin S.p.A.
• Eli Lilly and Company
• FUJIFILM Holdings Corporation
• GE HealthCare
• Hologic Inc.
• Illumina Inc.
• Koninklijke Philips N.V.
• Labcorp
• Merck KGaA
• Myriad Genetics Inc.
• QIAGEN N.V.
• Quest Diagnostics Inc.
• Siemens Healthineers

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.